Carroll Financial Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Carroll Financial Associates’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$0	Sell	4 -17	-81%	-$1.85K	﹤0.01%	2052
2021 Q3	$2K	Sell	21 -988	-98%	-$103K	﹤0.01%	1597
2021 Q2	$94K	Buy	1,009 +612	+154%	+$56.3K	0.01%	603
2021 Q1	$36K	Buy	+397	New	+$33.5K	﹤0.01%	848
2017 Q3	–	Sell	-700	Closed	-$8K	–	1304
2017 Q2	$8K	Hold	700	–	–	﹤0.01%	900
2017 Q1	$10K	Hold	700	–	–	﹤0.01%	845
2016 Q4	$11K	Hold	700	–	–	﹤0.01%	783
2016 Q3	$12K	Hold	700	–	–	﹤0.01%	784
2016 Q2	$11K	Hold	700	–	–	﹤0.01%	774
2016 Q1	$11K	Hold	700	–	–	﹤0.01%	758
2015 Q4	$15K	Hold	700	–	–	﹤0.01%	659
2015 Q3	$10K	Hold	700	–	–	﹤0.01%	726
2015 Q2	$24K	Buy	+700	New	+$21.4K	0.01%	521
2014 Q4	–	Sell	-700	Closed	-$9K	–	935
2014 Q3	$9K	Hold	700	–	–	﹤0.01%	587
2014 Q2	$11K	Buy	+700	New	+$9.99K	﹤0.01%	594

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Carroll Financial Associates's HZNP Position: Q4 2021 in Review

Carroll Financial Associates reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 81% in Q4 2021, selling an estimated $1.85K and leaving 4 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2052.

Carroll Financial Associates first reported a position in HZNP in Q2 2014 and has held it in 15 quarters since. The position peaked at $94K in Q2 2021. 611 funds tracked by Wall St. Rank hold HZNP as of Q4 2021.

Carroll Financial Associates held 4 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $0 as of Q4 2021.
Carroll Financial Associates sold 17 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2021, an estimated $1.85K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #2052 holding.
Carroll Financial Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and has held it in 15 quarters since.
Carroll Financial Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $94K in Q2 2021.
611 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.